Efficacy of leukotriene receptor antagonist with anti-H1 receptor antagonist plus anti-H2 receptor antagonist for treatment of refractory chronic idiopathic urticaria
- PMID: 24192062
- DOI: 10.3109/09546634.2013.849791
Efficacy of leukotriene receptor antagonist with anti-H1 receptor antagonist plus anti-H2 receptor antagonist for treatment of refractory chronic idiopathic urticaria
Erratum in
-
Erratum.J Dermatolog Treat. 2019 Nov;30(7):I. doi: 10.3109/09546634.2014.894287. Epub 2014 Mar 12. J Dermatolog Treat. 2019. PMID: 24617826 No abstract available.
Abstract
Background: The efficacy of the combination of leukotriene receptor antagonist (LRA) and H1 antihistamine was similar to the synergistic regimen of H1 and H2 antihistamine for treatment of chronic idiopathic urticaria (CIU). However, the effective rates of these two regimens were only 53.3% and 63.3%, respectively.
Method: A total of 50 with two combined therapeutic regimens treatment ineffective patients were evaluated. Patients were single blinded and randomly assigned to one of two medication groups that received the following regimens for 4 weeks: Group A (n = 30), combination of LRA, H1 antihistamine and H2 antihistamine. Group B (n = 20) continued with the previously taken two combination regimens. The treatment efficacy was measured by daily urticaria activity score (UAS) of wheal and itch. A positive therapeutic response was defined as a reduction to <25% of baseline weekly UAS, while a relapse was a return to >75% of baseline weekly UAS.
Results: At the end of 4 weeks, the UAS response to treatment of Group A was decreased from 35.2% to 21.2%, and the Group B was persisted with 33.9% as before the treatment.
Conclusion: The combination of LRA, H2 antihistamine and H1 antihistamine is promising for the refractory CIU cases, which were refractory for two combined therapeutic regimens.
Similar articles
-
Efficacy of leukotriene receptor antagonist with an anti-H1 receptor antagonist for treatment of chronic idiopathic urticaria.J Dermatolog Treat. 2009;20(4):194-7. doi: 10.1080/09546630802607495. J Dermatolog Treat. 2009. PMID: 19085267 Clinical Trial.
-
The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study.J Allergy Clin Immunol. 2002 Sep;110(3):484-8. doi: 10.1067/mai.2002.126676. J Allergy Clin Immunol. 2002. PMID: 12209099 Clinical Trial.
-
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.J Allergy Clin Immunol. 2011 Sep;128(3):567-73.e1. doi: 10.1016/j.jaci.2011.06.010. Epub 2011 Jul 18. J Allergy Clin Immunol. 2011. PMID: 21762974 Clinical Trial.
-
[Bibliographic review of antihistaminics H2 in the treatment of chronic (or recurrent) idiopathic urticaria].Allerg Immunol (Paris). 1988 Dec;20(10):377-8. Allerg Immunol (Paris). 1988. PMID: 2905603 Review. French.
-
Leukotriene Receptor Antagonist Addition to H1-Antihistamine Is Effective for Treating Allergic Rhinitis: A Systematic Review and Meta-analysis.Am J Rhinol Allergy. 2019 Sep;33(5):591-600. doi: 10.1177/1945892419844459. Epub 2019 Apr 22. Am J Rhinol Allergy. 2019. PMID: 31007040 No abstract available.
Cited by
-
Effectiveness and Safety of Immunosuppressants and Biological Therapy for Chronic Spontaneous Urticaria: A Network Meta-Analysis.Biomedicines. 2022 Sep 1;10(9):2152. doi: 10.3390/biomedicines10092152. Biomedicines. 2022. PMID: 36140253 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials